Peripheral blood samples were drawn from participants with standardized phlebotomy procedures and collected into an EDTA tube. After blood samples were centrifuged at 2000× g, plasma was isolated from the supernatants and then immediately aliquoted, transferred into plain polypropylene tubes, and stored in a dedicated freezer at −80 °C until use. A total of 121 plasma samples from patients were obtained from Chang Gung Memorial Hospital (Linkou, Taiwan) after informed consent had been acquired from all subjects. Of them, those with distant metastasis when the blood was drawn and tested for targeted molecules were designated as M1 (n = 44); while those without distant metastasis were designated as M0 (n = 27). Meanwhile, a cohort of 50 patients with gallstones (GS) subjected for elective cholecystectomy served as controls. Pathological staging of pancreatic cancer was based on AJCC edition 8. The detailed clinicopathological features are shown in Supplementary Table S4 . The concentration of CA19-9 was measured by electrochemiluminescence immunoassay (ECLIA) with Roche cobas® 8000 e602 analyzer (Roche Diagnostics, Rotkreuz, Switzerland).
Cobas 8000 e602 analyzer
Manufactured by Roche
Sourced in Germany, Switzerland, France
The Cobas 8000 e602 analyzer is a laboratory instrument designed for the in-vitro quantitative determination of analytes in biological samples. It utilizes electrochemiluminescence (ECL) technology to perform immunoassay testing. The core function of the Cobas 8000 e602 analyzer is to automate the analytical process, providing efficient and reliable results for clinical diagnostics.
Automatically generated - may contain errors
Lab products found in correlation
Elecsys vitamin d total electrochemiluminescence binding assay, by Roche (3 mentions)
Architect i2000sr platform, by Abbott (2 mentions)
Elecsys troponin t hs stat, by Roche (2 mentions)
Architect anti hbs reagent kit, by Abbott (1 mentions)
Cobas 8000 c702 analyzer, by Roche (1 mentions)
Bek 2211, by Biosensis (1 mentions)
Hlc 723 g8 analyzer, by Tosoh (1 mentions)
Cobas 8000 e801 analyzer, by Roche (1 mentions)
Cobas 8000 c502 analyzer, by Roche (1 mentions)
Elecsys anti sars cov 2 s immunoassay, by Roche (1 mentions)
Anti sars cov 2 immunoassay, by Roche (1 mentions)
Cobas 8000 c702, by Roche (1 mentions)
Vacutainer system, by BD (1 mentions)
Cobas e801 analyzer, by Roche (1 mentions)
Cobas c702, by Roche (1 mentions)
Enzyme linked immunosorbent assay kit, by R&D Systems (1 mentions)
25 protocols using cobas 8000 e602 analyzer
1
Plasma Biomarker Assessment in Metastatic Pancreatic Cancer
2
Fasting Blood Lipid and Hormone Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Venous blood sample from all participants was performed in the morning after 12-hour overnight fasting. All serum metabolic parameters and reproductive hormones were measured during the first visit. Serum levels of TG, TC, HDL-C, LDL-C, lipoprotein(a) [Lp(a)], apolipoprotein A-I (Apo A-I), and apolipoprotein B (Apo B) were analyzed by using standard enzymatic and colorimetric methods on Abbott Architect C16000/C1600757 Automatic Biochemical Analyzer (Abbott Diagnostics, Abbott Park, IL). The serum concentrations of reproductive hormones, including estradiol, follicle-stimulating hormone, luteinizing hormone, and progesterone, were determined by electrochemiluminescent immunoassay using a Roche Cobas 8000 e602 Analyzer (Roche Diagnostics, Meylan, France). According to the guidelines, fasting TC values of ≥6.2 mmol/L were used to characterize hypercholesterolemia,[14 (link)] while serum TG levels ≥1.7 mmol/L were used to define hypertriglyceridemia.[15 (link)]
3
Vitamin D Measurement Techniques
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For NationMS, vitD was measured as the serum level of 25(OH)D3. Measurement was performed in NationMS for n = 761 patients with a commercially available kit for liquid chromatography-mass spectrometry (LC-MS/MS) (Recipe) on a Shimadzu 8040 LC–MS/MS instrument coupled to a UHPLC system (Nexera, Shimadzu). For BIONAT, total 25(OH)D2+3 measurements were available for 579 patients. Total vitD has been measured using a commercially available electro-chemiluminescence competitive 25-hydroxyvitamin D binding assay (Cobas, Roche), and quantified on a Roche Cobas 8000 e602 analyzer (Roche Diagnostics). As food-derived vitD2 only contributes little to total serum vitD levels, there are only minimal differences between total vitD and vitD3 serum levels.
4
Serum 25(OH)D and Acute Phase Response
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Herein, the exposure variable was vitamin D. In humans, the most common form of vitamin D is serum 25(OH)D, and prior reports suggested that serum 25(OH)D content can accurately predict a patient’s vitamin D status. The baseline serum 25(OH)D content was recorded immediately upon admission using an automated electrochemiluminescence immunoassay on a Roche Cobas 8000/e602 analyzer (Roche Diagnostics, Mannheim, Germany). Currently, there is no standard 25(OH)D threshold value for determining APR risk. However, the Institute of Medicine (National Academy of Sciences, Washington, DC, USA) and the National Osteoporosis Society (Bath, England) agreed that a serum 25(OH)D content of (2.5 nmol/L 25[OH]D = 1 ng/mL 25[OH]D) of < 30 nmol/L (12ng/mL) is deficient, 30-50 nmol/l (12-20 ng/mL) is insufficient for certain individuals, and >50 nmol/L (20 ng/mL) is sufficient for most individuals (18 (link), 19 ). The time of blood collection was also analyzed in this study. Lastly, seasons were described as: Spring, March–May; Summer, June–August; Autumn, September–November; and Winter, December–February.
5
Quantifying Anti-HAV Antibody Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were obtained prior to the 1st dose and at 4 to 6 weeks after the 2nd dose. The blood samples were immediately centrifuged and stored at −70°C until assayed. Antibody concentrations were quantified by electrochemiluminescence immunoassays using Elecsys Anti-HAV assays (Roche Diagnostics GmbH, Mannheim, Germany) on a Cobas 8000 e 602 analyzer (Roche Diagnostics GmbH) at Neodin Research Institute (Seoul, Korea). Anti-HAV immunoglobulin (Ig) G levels greater than or equal to 20 mIU/mL were considered seropositive.[27 (link)]
6
Measuring Vitamin D and VDBP Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
VDBP concentration was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. Coefficients of variation (CVs) for three concentrations (10.9, 31.7, and 63.7 μg/ml) by intra- and interassay were 5.76.2% and 5.17.4%, respectively [19 ]. Total 25(OH)D concentration was measured using an Elecsys vitamin D total electrochemiluminescence binding assay (Roche Diagnostics, Mannheim, Germany) and a Cobas 8000 e602 analyzer (Roche Diagnostics). CVs for four concentrations (6.8, 15.0, 28.0, and 67.0 ng/ml) of intra- and interassay were 1.7-7.8% and 2.210.7%, respectively [20 ].
7
Determination of Antibody Titers in IVIG
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The anti-HAV antibody titers of all IVIG preparations were determined by electro-chemiluminescence immunoassay using an Elecsys Anti-HAV II kit and a Cobas 8000 e602 analyzer (Roche Diagnostics, Mannheim, Germany). Anti-hepatitis B surface (anti-HBs) antibody titers were measured by chemiluminescent microparticle immunoassay using an ARCHITECT Anti-HBs Reagent Kit and an ARCHITECT i400 immunoassay analyzer (Abbott Laboratories, Lake Bluff, IL, USA). These experiments were performed by Seegene Medical Foundation (Seoul, Korea). The lower limits of detection for anti-HAV and anti-HBs antibodies were 3 mIU/mL and 10 mIU/mL, respectively, in this assay system.
8
Vitamin D Metabolite Quantification
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For CSF sample, only total 25(OH)D level was measured. For serum sample, VDBP level was also measured to calculate bioavailable concentration with total 25(OH)D. VDBP was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. Total 25(OH)D was measured using Elecsys Vitamin D Total Electrochemiluminescence Binding Assay (Roche Diagnostics, Mannheim, Germany) with a Cobas 8000 e602 analyzer (Roche Diagnostics).
9
CSF and Serum Biomarkers in NT1
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CSF samples were collected between 5:00 and 7:00 pm in all participants (n = 104), while blood samples were collected after overnight fasting between 7:00 and 7:30 am in 93 participants (63 patients with NT1 and 30 controls). After centrifugation, aliquots of CSF were immediately frozen and stored immediately at −80°C. CSF ORX‐A level was determined in duplicate using the I125‐radioimmunoassay (RIA) kit from Phoenix Pharmaceuticals, Inc (Belmont, CA, USA), according to the manufacturer's recommendations. Serum and CSF ferritin (Ser‐Ferr and CSF‐Ferr) levels were estimated by electrochemiluminiscence on Cobas 8000 e602© analyzer (Roche Diagnostics, Meylan, France) following the manufacturer's instructions.
10
Troponin T Measurement in TAVI Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
High‐sensitivity troponin T measurement was performed on the Cobas 8000/e602 analyzer (Roche Diagnostics) the day before and the day after the procedure in all included patients. The 99% upper reference limit for this kit is 0.014 μg/L. The total imprecision at the 99th percentile is <6.5%. The limit of detection of this assay is 0.005 μg/L. For patients requiring revascularization before TAVI, percutaneous coronary intervention (PCI) was performed at least 10 days before the valve intervention. Clinical and echocardiographic data at baseline and follow‐up were prospectively collected by dedicated personnel and entered in a local database and national registries.15 , 16 The primary end point of this study was 1‐year mortality. Secondary end points consisted of 30‐day mortality, 3‐year mortality, stroke, myocardial injury, new pacemaker implantation, major vascular complication, paravalvular regurgitation greater than mild, and acute kidney injury. End points were defined according to the VARC‐2 criteria.12
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!